This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caggana, M. Articles by Wrensch, M. R. Search for Related Content PubMed PubMed Citation Articles by Caggana, M. Articles by Wrensch, M. R.

Associations Between ERCC2 Polymorphisms and Gliomas¹

Division of Genetic Disorders, New York State Department of Health, Wadsworth Center, Albany, New York 12201 [M. C., J. K., J. M. C.]; Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, California 94143 [J. K. W., R. M., P. C., M. R. W.]; and Department of Cancer Biology, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115 [K. T. K.]

Xeroderma pigmentosum complementation group D/excision repair cross-complementing in rodents 2 (ERCC2) encodes a protein that is part of the nucleotide excision repair pathway and the transcription factor IIH transcription complex. Mutations in this gene have been shown to cause three distinct clinical diseases including xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Several ERCC2 polymorphisms, the effects of which on gene function are not known, have been described. To investigate whether constitutive sequence variations might be associated with adult onset gliomas, blood specimens from a case-control study (187 cases and 169 controls) were genotyped for seven previously described polymorphisms (R156R, I199M, H201Y, D312N, A575A, D711D, and K751Q). A novel R616C polymorphism was also identified. Cases were significantly more likely than controls to be homozygous for the silent AA variant at codon 156 (odds ratio, 2.3; 95% confidence interval, 1.3–4.2). Although this was observed for patients in each of three histological subgroups of cases, (glioblastoma multiforme, astrocytoma, and oligoastrocytoma) compared with controls, the association was strongest for patients with oligoastrocytoma (odds ratio, 3.2; 95% confidence interval, 1.1–9.5). In contrast, cases were somewhat less likely than controls to carry variants at D312N, D711D, and K751Q, but not significantly so overall or for any subgroup after adjustment for age and gender. Individuals with variant nucleotides at D312N, D711D, and K751Q were significantly more likely to carry a variant at another of those three codons and less likely to carry a variant nucleotide at R156R, regardless of case or control status. Although the pattern of association observed here is consistent with a role of ERCC2 variants in the prevention or causation of glioma, these results are also consistent with the possibility that another gene linked to ERCC2 may be involved. This seems especially so because the strongest association was observed with a silent nucleotide variation.

This article has been cited by other articles:

				F. Wang, D. Chang, F.-l. Hu, H. Sui, B. Han, D.-d. li, and Y.-s. Zhao DNA Repair Gene XPD Polymorphisms and Cancer Risk: A Meta-analysis Based on 56 Case-Control Studies Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 507 - 517. [Abstract] [Full Text] [PDF]

				B. M. Costa, P. Ferreira, S. Costa, P. Canedo, P. Oliveira, A. Silva, F. Pardal, G. Suriano, J. C. Machado, J. M. Lopes, et al. Association between Functional EGF+61 Polymorphism and Glioma Risk Clin. Cancer Res., May 1, 2007; 13(9): 2621 - 2626. [Abstract] [Full Text] [PDF]

				J. Bigler, C. M. Ulrich, T. Kawashima, J. Whitton, and J. D. Potter DNA Repair Polymorphisms and Risk of Colorectal Adenomatous or Hyperplastic Polyps Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2501 - 2508. [Abstract] [Full Text] [PDF]

				M. Wrensch, K. T. Kelsey, M. Liu, R. Miike, M. Moghadassi, J. D. Sison, K. Aldape, A. McMillan, J. Wiemels, and J. K. Wiencke ERCC1 and ERCC2 polymorphisms and adult glioma Neuro-oncol, October 1, 2005; 7(4): 495 - 507. [Abstract] [PDF]

				S. Benhamou and A. Sarasin ERCC2 /XPD Gene Polymorphisms and Lung Cancer: A HuGE Review Am. J. Epidemiol., January 1, 2005; 161(1): 1 - 14. [Abstract] [Full Text] [PDF]

				C. Justenhoven, U. Hamann, B. Pesch, V. Harth, S. Rabstein, C. Baisch, C. Vollmert, T. Illig, Y.-D. Ko, T. Bruning, et al. ERCC2 Genotypes and a Corresponding Haplotype Are Linked with Breast Cancer Risk in a German Population Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2059 - 2064. [Abstract] [Full Text] [PDF]

				D. A. Hill, P. D. Inskip, W. R. Shapiro, R. G. Selker, H. A. Fine, P. M. Black, and M. S. Linet Cancer in First-Degree Relatives and Risk of Glioma in Adults Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1443 - 1448. [Abstract] [Full Text] [PDF]

				W.-M. Gao, M. Romkes, R. D. Day, J. M. Siegfried, J. D. Luketich, H. H. Mady, M. F. Melhem, and P. Keohavong Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer Carcinogenesis, October 1, 2003; 24(10): 1671 - 1676. [Abstract] [Full Text] [PDF]

				B. A. Nexo, U. Vogel, A. Olsen, T. Ketelsen, Z. Bukowy, B. L. Thomsen, H. Wallin, K. Overvad, and A. Tjonneland A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55 Carcinogenesis, May 1, 2003; 24(5): 899 - 904. [Abstract] [Full Text] [PDF]

				J. Yin, E. Rockenbauer, M. Hedayati, N. R. Jacobsen, U. Vogel, L. Grossman, L. Bolund, and B. A. Nexo Multiple Single Nucleotide Polymorphisms on Human Chromosome 19q13.2-3 Associate with Risk of Basal Cell Carcinoma Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1449 - 1453. [Abstract] [Full Text] [PDF]

				M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. S. Berger Epidemiology of primary brain tumors: Current concepts and review of the literature Neuro-oncol, October 1, 2002; 4(4): 278 - 299. [Abstract] [PDF]

				M. C. Stern, L. R. Johnson, D. A. Bell, and J. A. Taylor XPD Codon 751 Polymorphism, Metabolism Genes, Smoking, and Bladder Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1004 - 1011. [Abstract] [Full Text] [PDF]

				E. M. Sturgis, K. R. Dahlstrom, M. R. Spitz, and Q. Wei DNA Repair Gene ERCC1 and ERCC2/XPD Polymorphisms and Risk of Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, September 1, 2002; 128(9): 1084 - 1088. [Abstract] [Full Text] [PDF]

				E. Rockenbauer, M. H. Bendixen, Z. Bukowy, J. Yin, N. R. Jacobsen, M. Hedayati, U. Vogel, L. Grossman, L. Bolund, and B. A. Nexo Association of chromosome 19q13.2-3 haplotypes with basal cell carcinoma: tentative delineation of an involved region using data for single nucleotide polymorphisms in two cohorts Carcinogenesis, July 1, 2002; 23(7): 1149 - 1153. [Abstract] [Full Text] [PDF]

				D. J. Park, J. Stoehlmacher, W. Zhang, D. D. Tsao-Wei, S. Groshen, and H.-J. Lenz A Xeroderma Pigmentosum Group D Gene Polymorphism Predicts Clinical Outcome to Platinum-based Chemotherapy in Patients with Advanced Colorectal Cancer Cancer Res., December 1, 2001; 61(24): 8654 - 8658. [Abstract] [Full Text] [PDF]

				H. Seker, D. Butkiewicz, E. D. Bowman, M. Rusin, M. Hedayati, L. Grossman, and C. C. Harris Functional Significance of XPD Polymorphic Variants: Attenuated Apoptosis in Human Lymphoblastoid Cells with the XPD 312 Asp/Asp Genotype Cancer Res., October 1, 2001; 61(20): 7430 - 7434. [Abstract] [Full Text] [PDF]